APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Syncytial Virus Vaccine for the Elderly

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchRespiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Syncytial Virus Vaccine for the Elderly Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Respiratory Syncytial Virus Vaccine for the Elderly market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Respiratory Syncytial Virus Vaccine for the Elderly market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Respiratory Syncytial Virus Vaccine for the Elderly market include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Syncytial Virus Vaccine for the Elderly market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Syncytial Virus Vaccine for the Elderly and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Syncytial Virus Vaccine for the Elderly market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company

GSK

Icosavax

Moderna

Pfizer

RNAimmune

Sanofi

Advaccine

Daiichi Sankyo

Immorna

Blue Lake Biotechnology

Clover Biopharma

Innorna

Starna Therapeutics

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

Recombinant Protein Vaccine

Nucleic Acid Vaccines

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Respiratory Syncytial Virus Vaccine for the Elderly status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Respiratory Syncytial Virus Vaccine for the Elderly market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Respiratory Syncytial Virus Vaccine for the Elderly significant trends, drivers, influence factors in global and regions.

6. To analyze Respiratory Syncytial Virus Vaccine for the Elderly competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for the Elderly market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Syncytial Virus Vaccine for the Elderly industry.

Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Respiratory Syncytial Virus Vaccine for the Elderly in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends Table 2. Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers Table 3. Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges Table 4. Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Company (2021-2026) Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Company (Units) & (2021-2026) Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Company (2021-2026) Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Company Ranking, (2024-2026) & (USD Million) Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Key Company Manufacturing Base & Headquarters Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Company, Product Type & Application Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Protein Vaccine Table 18. Significant Companies of Nucleic Acid Vaccines Table 19. Significant Companies of Others Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2021-2026) & (Units) Table 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2027-2032) & (Units) Table 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Type (2021-2026) Table 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Type (2027-2032) Table 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type (2021-2026) Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Centers for Disease Control and Prevention Table 32. Significant Companies of Others Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 34. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2021-2026) & (Units) Table 35. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2027-2032) & (Units) Table 36. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Application (2021-2026) Table 37. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Application (2027-2032) Table 38. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application (2021-2026) Table 42. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application (2027-2032) Table 43. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 44. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Units) Table 45. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026) Table 46. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032) & (Units) Table 47. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2027-2032) Table 48. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Region (2021-2026) Table 51. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Region (2027-2032) Table 53. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 56. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 58. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026) Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2027-2032) Table 61. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Market Share by Country (2021-2026) Table 63. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Market Share by Country (2027-2032) Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 69. GSK Recent Development Table 70. Icosavax Company Information Table 71. Icosavax Business Overview Table 72. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 74. Icosavax Recent Development Table 75. Moderna Company Information Table 76. Moderna Business Overview Table 77. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 79. Moderna Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 84. Pfizer Recent Development Table 85. RNAimmune Company Information Table 86. RNAimmune Business Overview Table 87. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 89. RNAimmune Recent Development Table 90. Sanofi Company Information Table 91. Sanofi Business Overview Table 92. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 94. Sanofi Recent Development Table 95. Advaccine Company Information Table 96. Advaccine Business Overview Table 97. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 99. Advaccine Recent Development Table 100. Daiichi Sankyo Company Information Table 101. Daiichi Sankyo Business Overview Table 102. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 104. Daiichi Sankyo Recent Development Table 105. Immorna Company Information Table 106. Immorna Business Overview Table 107. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 109. Immorna Recent Development Table 110. Blue Lake Biotechnology Company Information Table 111. Blue Lake Biotechnology Business Overview Table 112. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 114. Blue Lake Biotechnology Recent Development Table 115. Clover Biopharma Company Information Table 116. Clover Biopharma Business Overview Table 117. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 119. Clover Biopharma Recent Development Table 120. Innorna Company Information Table 121. Innorna Business Overview Table 122. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 124. Innorna Recent Development Table 125. Starna Therapeutics Company Information Table 126. Starna Therapeutics Business Overview Table 127. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 129. Starna Therapeutics Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List Table 133. Respiratory Syncytial Virus Vaccine for the Elderly Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Respiratory Syncytial Virus Vaccine for the Elderly Product Image Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032) & (US$ Million) Figure 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2032) & (Units) Figure 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Protein Vaccine Image Figure 10. Nucleic Acid Vaccines Image Figure 11. Others Image Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Type (2021-2032) Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Centers for Disease Control and Prevention Image Figure 20. Others Image Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Application (2021-2032) Figure 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application (2021-2032) Figure 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032) & (US$ Million) Figure 32. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032) & (US$ Million) Figure 38. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Respiratory Syncytial Virus Vaccine for the Elderly Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Nucleic Acid Vaccines
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • GSK
  • Icosavax
  • Moderna
  • Pfizer
  • RNAimmune
  • Sanofi
  • Advaccine
  • Daiichi Sankyo
  • Immorna
  • Blue Lake Biotechnology
  • Clover Biopharma
  • Innorna
  • Starna Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032)
  4. 1.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (2021-2032)
  5. 1.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
  1. 2.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
  2. 2.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
  3. 2.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
  4. 2.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
3 Respiratory Syncytial Virus Vaccine for the Elderly Market by Company
  1. 3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Revenue Ranking in 2025
  2. 3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026)
  3. 3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Company (2021-2026)
  4. 3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price by Company (2021-2026)
  5. 3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Ranking (2024-2026)
  6. 3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Manufacturing Base and Headquarters
  7. 3.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Product Type and Application
  8. 3.8 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Respiratory Syncytial Virus Vaccine for the Elderly Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
  1. 4.1 Respiratory Syncytial Virus Vaccine for the Elderly Type Introduction
  2. 4.1.1 Recombinant Protein Vaccine
  3. 4.1.2 Nucleic Acid Vaccines
  4. 4.1.3 Others
  5. 4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type
  6. 4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type
  10. 4.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2021-2032)
  12. 4.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type (2021-2032)
5 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
  1. 5.1 Respiratory Syncytial Virus Vaccine for the Elderly Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application
  6. 5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application
  10. 5.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2021-2032)
  12. 5.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application (2021-2032)
6 Respiratory Syncytial Virus Vaccine for the Elderly Regional Sales and Value Analysis
  1. 6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021-2026
  4. 6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032)
  5. 6.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region (2021-2032)
  7. 6.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region: 2021-2026
  8. 6.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region (2027-2032)
  9. 6.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032)
  12. 6.6.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032)
  15. 6.7.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032)
  21. 6.9.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2025 VS 2032
7 Respiratory Syncytial Virus Vaccine for the Elderly Country-level Sales and Value Analysis
  1. 7.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  4. 7.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
  5. 7.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032)
  6. 7.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2021-2032)
  7. 7.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2021-2026)
  8. 7.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Icosavax
  8. 8.2.1 Icosavax Company Information
  9. 8.2.2 Icosavax Business Overview
  10. 8.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  12. 8.2.5 Icosavax Recent Developments
  13. 8.3 Moderna
  14. 8.3.1 Moderna Company Information
  15. 8.3.2 Moderna Business Overview
  16. 8.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  18. 8.3.5 Moderna Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 RNAimmune
  26. 8.5.1 RNAimmune Company Information
  27. 8.5.2 RNAimmune Business Overview
  28. 8.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  30. 8.5.5 RNAimmune Recent Developments
  31. 8.6 Sanofi
  32. 8.6.1 Sanofi Company Information
  33. 8.6.2 Sanofi Business Overview
  34. 8.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  36. 8.6.5 Sanofi Recent Developments
  37. 8.7 Advaccine
  38. 8.7.1 Advaccine Company Information
  39. 8.7.2 Advaccine Business Overview
  40. 8.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  42. 8.7.5 Advaccine Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Immorna
  50. 8.9.1 Immorna Company Information
  51. 8.9.2 Immorna Business Overview
  52. 8.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  54. 8.9.5 Immorna Recent Developments
  55. 8.10 Blue Lake Biotechnology
  56. 8.10.1 Blue Lake Biotechnology Company Information
  57. 8.10.2 Blue Lake Biotechnology Business Overview
  58. 8.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  60. 8.10.5 Blue Lake Biotechnology Recent Developments
  61. 8.11 Clover Biopharma
  62. 8.11.1 Clover Biopharma Company Information
  63. 8.11.2 Clover Biopharma Business Overview
  64. 8.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  66. 8.11.5 Clover Biopharma Recent Developments
  67. 8.12 Innorna
  68. 8.12.1 Innorna Company Information
  69. 8.12.2 Innorna Business Overview
  70. 8.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  72. 8.12.5 Innorna Recent Developments
  73. 8.13 Starna Therapeutics
  74. 8.13.1 Starna Therapeutics Company Information
  75. 8.13.2 Starna Therapeutics Business Overview
  76. 8.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  78. 8.13.5 Starna Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
  2. 9.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales Mode & Process
  6. 9.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
  9. 9.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst